학술논문
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
Document Type
Article
Author
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, January 2024, 24(1):25-35)
Subject
Language
English
ISSN
14744457
14733099
14733099